Breast Cancer

The ODAC has noted there was no clinical benefit of camizestrant for patients with HR+/HER2– advanced or metastatic breast cancer with ESR1 mutation and radiographic progression.

Read this to learn 3 things you should know about the first-line treatment of mTNBC with TROP2-directed ADCs.

Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.

New findings presented at the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Surgical approach and adherence to endocrine therapy were predictors of locoregional recurrence in women diagnosed with breast cancer at age 40 or younger.

Explore how ADCs, ctDNA monitoring, and new endocrine options reshape metastatic breast cancer care, as well as sequencing and toxicity tips from experts.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI algorithm can complement tools such as the Tyrer-Cuzick model to define breast cancer risks.

Elizabeth Mittendorf, MD, PhD, discusses Clarity Breast, an FDA-authorized AI tool that predicts 5-year breast cancer risk using standard 2D mammograms.

Young patients with breast cancer should always aim to advocate for themselves, said Shari Goldfarb, MD.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI tool utilizes mammography to predict 5-year breast cancer risk.

Natalie Berger, MD, discusses the evolving landscape of ADC sequencing in breast cancer, the role of HER2 expression, and the "sandwich approach" to treatment.

A statistically significant pCR rate was noted in patients with HER2+ breast cancer treated with anbenitamab injection and albumin-bound docetaxel.

The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.

ECG changes and cardiac biomarkers were evaluated in patients with breast cancer to identify early markers of chemotherapy-induced cardiotoxicity.

Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.

This study aims to understand the degree of influence of the severity of lymphedema on quality of life in patients with breast cancer–related lymphedema during the maintenance phase.

In the non-HLA-A*02 arm of the FLAMINGO-1 trial, breast recurrence rates were less than 1% following treatment with GLSI-100.

The primary end point of PFS was met in the phase 3 FOURLIGHT-1 trial assessing atirmociclib plus fulvestrant in patients with HR+/HER2– breast cancer.

Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.